clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- Clin. Infect. Dis. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Carlson LD et al. | Standardized BACTEC method to measure clarithromycin susceptibility of Mycobacterium genavense. | 1998 | J. Clin. Microbiol. | pmid:9508306 |
| Sato K et al. | Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. | 1998 | J. Antimicrob. Chemother. | pmid:9511040 |
| Moayyedi P | Amoxycillin dual therapy against Helicobacter pylori--the final nail in the coffin? | 1997 | Ital J Gastroenterol Hepatol | pmid:9513823 |
| Williamson R et al. | New options in Helicobacter pylori eradication: efficacy, resistance and synergy. | 1998 | Scand. J. Gastroenterol. Suppl. | pmid:9515751 |
| Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. | 1998 | Am. J. Gastroenterol. | pmid:9517644 |
| Adamek RJ et al. | Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. | 1998 | Am. J. Gastroenterol. | pmid:9517645 |
| Trevisani L et al. | A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. | 1998 | Am. J. Gastroenterol. | pmid:9517646 |
| Hafner R et al. | Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. | 1998 | Antimicrob. Agents Chemother. | pmid:9517944 |
| Fattorini L et al. | Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. | 1998 | Antimicrob. Agents Chemother. | pmid:9517960 |
| Trivedi S et al. | Clarithromycin and digoxin toxicity. | 1998 | Ann. Intern. Med. | pmid:9518419 |
| Laine L and Fendrick AM | Helicobacter pylori and peptic ulcer disease. Bridging the gap between knowledge and treatment. | 1998 | Postgrad Med | pmid:9519040 |
| Alegre Herrera S et al. | [Clarithromycin-carbamazepine interaction: neurological symptoms and hyponatremia]. | 1998 | An Med Interna | pmid:9522506 |
| Berquist WE | New, improved Helicobacter pylori eradication therapy in children. | 1998 | J. Pediatr. Gastroenterol. Nutr. | pmid:9523877 |
| Collins LA et al. | Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 | Antimicrob. Agents Chemother. | pmid:9527783 |
| Kashuba AD and Amsden GW | Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9527816 |
| Gisbert JP et al. | [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic]. | 1998 | Med Clin (Barc) | pmid:9527978 |
| Perng CL et al. | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. | 1998 | Dig. Dis. Sci. | pmid:9539638 |
| Oberg KC | Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. | 1998 Mar-Apr | Pharmacotherapy | pmid:9545160 |
| Treiber G et al. | Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. | 1998 | Helicobacter | pmid:9546119 |
| Suzuki J et al. | Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. | 1998 | Helicobacter | pmid:9546120 |
| Lindsetmo RO et al. | Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy. | 1998 | Scand. J. Gastroenterol. | pmid:9548613 |
| Comet R et al. | [Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection]. | 1998 | Gastroenterol Hepatol | pmid:9549183 |
| Carnicer J | [Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?]. | 1998 | Gastroenterol Hepatol | pmid:9549199 |
| Iwata M et al. | [Three cases of Fitz-Hugh-Curtis syndrome detected in the early stage by abdominal ultrasonography]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9549331 |
| Scheen AJ | [Drug clinics. The drug of the month. Ranitidine bismuth citrate (Pylorid)]. | 1998 | Rev Med Liege | pmid:9555183 |
| Cheng KL et al. | Effect of grapefruit juice on clarithromycin pharmacokinetics. | 1998 | Antimicrob. Agents Chemother. | pmid:9559810 |
| Hoppe JE and Bryskier A | In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). | 1998 | Antimicrob. Agents Chemother. | pmid:9559823 |
| Sonnenberg A et al. | Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. | 1998 | Arch. Intern. Med. | pmid:9570170 |
| Dal Bo' N et al. | Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks? | 1998 | J. Gastroenterol. Hepatol. | pmid:9570242 |
| O'Connor HJ et al. | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? | 1998 | Aliment. Pharmacol. Ther. | pmid:9570262 |
| Scott BB | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9570263 |
| Jarboe E et al. | Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin. | 1998 | Diagn. Microbiol. Infect. Dis. | pmid:9572027 |
| Elliott RL et al. | Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. | 1998 | J. Med. Chem. | pmid:9572890 |
| Griesgraber G et al. | Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. | 1998 | J. Med. Chem. | pmid:9572891 |
| Malfertheiner P and Blum AL | [Helicobacter pylori infection and ulcer]. | 1998 | Chirurg | pmid:9576033 |
| Lee KL et al. | QT prolongation and Torsades de Pointes associated with clarithromycin. | 1998 | Am. J. Med. | pmid:9576415 |
| Schwartz H et al. | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. | 1998 | Am. J. Gastroenterol. | pmid:9576452 |
| Felmingham D et al. | Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season. | 1998 | J. Antimicrob. Chemother. | pmid:9578171 |
| Tatsis G et al. | Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections. | 1998 | J. Antimicrob. Chemother. | pmid:9579716 |
| Sheu BS et al. | One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy. | 1998 | J. Formos. Med. Assoc. | pmid:9585678 |
| Hasegawa M et al. | [In vitro activities of faropenem against clarithromycin resistance Helicobacter pylori isolates]. | 1998 | Kansenshogaku Zasshi | pmid:9585692 |
| Sousa C et al. | [Cholestatic hepatitis probably induced by clarithromycin]. | 1997 | Gastroenterol. Clin. Biol. | pmid:9587506 |
| Chen S et al. | [Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection]. | 1996 | Zhonghua Nei Ke Za Zhi | pmid:9592303 |
| Liu W et al. | [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. | 1996 | Zhonghua Nei Ke Za Zhi | pmid:9592304 |
| Goldstein EJ et al. | Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. | 1998 | Antimicrob. Agents Chemother. | pmid:9593139 |
| Carr RA et al. | Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. | 1998 | Antimicrob. Agents Chemother. | pmid:9593146 |
| Sörberg M et al. | Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9593154 |
| Spangler SK et al. | Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. | 1998 | Antimicrob. Agents Chemother. | pmid:9593160 |
| van Aarem A et al. | Recurrent therapy resistant mastoiditis by Mycobacterium cheilonae abscessus, a nontuberculous mycobacterium. | 1998 | Int. J. Pediatr. Otorhinolaryngol. | pmid:9596371 |
| Koster F | Paradoxical local response to therapy for Mycobacterium avium complex infection in four patients with AIDS. | 1998 | Clin. Infect. Dis. | pmid:9597260 |